A Biomarker Exploration Study of Precision Treatment in Ovarian Cancer
NCT ID: NCT06483425
Last Updated: 2024-07-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
2000 participants
OBSERVATIONAL
2024-03-01
2028-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Looking at Biomarkers in Ovarian Cancer
NCT03419689
Study on the Dynamic Changes of Metabolic Biomarkers and Their Prognostic Relationship in Ovarian Cancer
NCT06019923
The Culture of Ovarian Cancer Organoids and Drug Screening
NCT04768270
The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer
NCT04582552
Bespoke ctDNA Assay for Recurrence and Treatment Response Monitoring in Advanced Epithelial Ovarian Cancer
NCT05446545
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ovarian cancer pateitns
Patients diagnosed with Ovarian cancer in Tongji Hospital, Wuhan.
Sequencing of DNA, RNA, and Proteins
Sequencing of DNA, RNA, and Proteins for Tumor, Blood, Ascite, and other samples before and after treatment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sequencing of DNA, RNA, and Proteins
Sequencing of DNA, RNA, and Proteins for Tumor, Blood, Ascite, and other samples before and after treatment.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willingness to undergo biomarker testing.
* Ability to provide informed consent for participation in the study.
Exclusion Criteria
* Previous participation in a conflicting clinical trial.
18 Years
80 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tongji Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Qinglei Gao
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-TJ-OCBiomarker
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.